Teleflex (TFX) said Thursday it has agreed to acquire most of Biotronik's Vascular Intervention business for about 760 million euros ($793.1 million) in cash, with the deal expected to close by the end of Q3.
The company said the acquisition will add coronary and peripheral vascular intervention devices to its portfolio.
The business generated a 5.4% constant currency revenue compound annual growth rate from 2022 to 2024 and is expected to contribute about 91 million euros in revenue in Q4 of 2025, Teleflex said.
Teleflex said it expects the purchase to add about $0.10 to adjusted earnings per share in the first year post-close.
Teleflex said it will finance the acquisition through a new term loan, revolving credit, and cash on hand.
Teleflex shares were more than 20% lower in recent trading.
Price: 150.73, Change: -26.90, Percent Change: -15.14
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。